GeneOne Life Science, Inc. (KRX:011000)

Market Cap	167.59B -22.5%
Revenue (ttm)	30.90B -18.6%
Net Income	-51.36B
EPS	-627.50
Shares Out	85.20M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,198,493
Average Volume	1,229,223
Open	1,968.00
Previous Close	1,967.00
Day's Range	1,965.00 - 2,200.00
52-Week Range	1,650.00 - 4,270.00
Beta	0.72
RSI	56.31
Earnings Date	Mar 18, 2026

About GeneOne Life Science

GeneOne Life Science, Inc., a biopharmaceutical company, engages in the research, development, and contract manufacturing of nucleic acid-based biopharmaceuticals. Its small molecule pipeline comprises GLS-1027, which is in Phase I clinical trial for treatment of nephropathy and inflammatory diseases; GLS-1200 that is in Phase II clinical trial to treat Rhinosinusitis; GLS-1027 and GLS-1200, which is Phase II clinical trial for treatment of COVID-19. The company’s nucleic acid vaccines include GLS-3000 mRNA under feasible study and GLS-5310 DNA...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1976
• Employees: 41
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 011000

Financial Performance

In 2024, GeneOne Life Science's revenue was 35.72 billion, a decrease of -11.15% compared to the previous year's 40.20 billion. Losses were -48.54 billion, -37.59% less than in 2023.